|
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
ABCB1 3435 was genotyped in 315 patients with epilepsy, classified as drug-resistant in 200 and drug-responsive in 115, and 200 control subjects without epilepsy.
|
12686700 |
2003 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients.
|
16753003 |
2006 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
ABCB1 3435C>T was genotyped in 746 Han Chinese patients with epilepsy and 179 controls.
|
17521963 |
2007 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
ABCB1 3435C>T was genotyped in 746 Han Chinese patients with epilepsy and 179 controls.
|
17521963 |
2007 |
|
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
P-glycoprotein (Pgp), a transmembrane transporter encoded by ABCB1 gene and located at the endothelial cells of the blood-brain barrier (BBB), has been associated with epilepsy pharmacoresistance.
|
18329296 |
2008 |
|
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
ABCB1 genotyping for epileptic patients is not warranted.
|
20491876 |
2010 |
|
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
ATP-binding cassette sub-family B member 1 (ABCB1) is a membrane-associated protein that acts as an efflux transporter for many substrates, including chemotherapeutic agents, anti-epilepsy medicine, antibiotics and drugs for PD.
|
24572589 |
2014 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
ABCB1 gene C3435T polymorphism and drug resistance in epilepsy: evidence based on 8,604 subjects.
|
25799371 |
2015 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
C3435T polymorphism of MDR1 gene was analysed by the high resolution melting technique in a group of patients with drug-resistant (n = 106) and drug-responsive epilepsy (n = 67), as well as in non-epileptic children (n = 98) hospitalised at the Department of Neurology, Polish Mother's Memorial Hospital in Lodz.
|
27391700 |
2016 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
rs776746 and rs15524 in the CYP3A5 gene tend to affect CBZ metabolism, and rs2032582, rs10234411 in the ABCB1 gene may contribute to inter-individual variation in CBZ and in CBZ-E transport among patients with epilepsy using CBZ in combination with PHT or PB.
|
26421491 |
2015 |
|
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
A total of 221 pediatric or adolescent Caucasian patients with epilepsy (105 females; age: 14.5+/-6.54 years) were genotyped for nine putatively functionally relevant ABCB1, ABCC2, CYP2C8, CYP2C9, and CYP2C19 polymorphisms.
|
19415824 |
2009 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
All the case-control association researches evaluating the role of MDR1 C3435T polymorphism in childhood epilepsy to antiepileptic drugs were identified.
|
24553780 |
2014 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
As compared with patients with drug-responsive epilepsy, patients with drug-resistant epilepsy were more likely to have the CC genotype at ABCB1 3435 than the TT genotype (odds ratio, 2.66; 95 percent confidence interval, 1.32 to 5.38; P=0.006).
|
12686700 |
2003 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association between ABCB1 polymorphisms and response to first-generation antiepileptic drugs in a Tunisian epileptic population.
|
29198163 |
2018 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy.
|
22972536 |
2012 |
|
Epilepsy
|
0.600 |
Therapeutic
|
disease |
RGD |
By compared to the epilepsy model group, the P-gp expression was not markedly attenuated by the inhibition of NF-κB activity with PDTC treatment, nevertheless with a decrease of NF-κB expression in this intervention group.
|
28303499 |
2017 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Conflicting reports suggest a possible association between variants of the MDR1 gene and medical intractability in epilepsy.
|
15679503 |
2005 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.
|
26122019 |
2016 |
|
Epilepsy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Exposing isolated rat brain capillaries to glutamate ex vivo upregulated P-gp expression to levels that were similar to those in capillaries isolated from rats that had status epilepticus or chronic epilepsy.
|
28195743 |
2017 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Further analysis using a logistic regression model revealed that only 2677G>T and 3435C>T in the ABCB1 gene and their interaction term were associated with drug-resistant epilepsy after adjustment for etiology and epilepsy classification.
|
17924830 |
2007 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Further analysis using a logistic regression model revealed that only 2677G>T and 3435C>T in the ABCB1 gene and their interaction term were associated with drug-resistant epilepsy after adjustment for etiology and epilepsy classification.
|
17924830 |
2007 |
|
Epilepsy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Further, for NF-κB p65, MDR1, P-gp and apoptosis-associated protein levels detection, miR-542-3p mimic showed a suppressive effect on these KA-induced protein levels, whereas TLR4 overexpression ameliorated the miR-542-3p-induced these protein levels in KA-treated epilepsy rats.
|
31702493 |
2019 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, patients with symptomatic epilepsies with the ABCB1_3435CT or TT genotypes had a lower risk of drug-resistance than those with the CC genotype.
|
20064729 |
2010 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese.
|
19450124 |
2009 |
|
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of the P-glycoprotein-encoding gene ABCB1 are suspected to be associated with pharmacoresistance phenotypes in epilepsy patients.
|
22033938 |
2011 |